Thus, FABP4 and MMP-9 serum levels could be used as non-invasive prognostic markers, especially to identify subgroups of NAFL and NASH patients likely to experience disease progression or not. This evidence concerns the gene MMP9 and metabolic dysfunction-associated steatohepatitis.